Impact of CYP2C19 Polymorphisms on Medical and Surgical Management of GERD: Implications for Personalized Therapy

Highlight

• Proton pump inhibitor (PPI) effectiveness in GERD is significantly influenced by CYP2C19 genetic polymorphisms affecting drug metabolism.
• Surgically treated patients with GERD exhibit a higher prevalence of CYP2C19 rapid and ultrarapid metabolizer phenotypes compared to medically managed patients.
• CYP2C19 testing could guide PPI dose adjustments and early surgical referral to optimize GERD management outcomes.
• This study is among the first to demonstrate the clinical utility of pharmacogenomic profiling in adult GERD treatment strategies.

Study Background